Enhancement of the surface expression of tumor necrosis factor α (TNFα) but not the p55 TNFα receptor in the THP-1 monocytic cell line by matrix metalloprotease inhibitors

Biochemical Pharmacology

Volumn 57, Issue 3, 1999, Pages 291-302

  Glaser, Keith B ^a   Pease, Lori ^a   Li, Junling ^a   Morgan, Douglas W ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Fluorescence activated cell sorting (FACS); Matrix metalloprotease inhibitors; THP 1 cells; Tumor necrosis factor (TNF ); Tumor necrosis factor converting enzyme (TACE); Tumor necrosis factor receptors I and II

Indexed keywords

[4 (N HYDROXYAMINO) 2 ISOBUTYL 3 (PHENYLTHIOMETHYL)SUCCINYL]PHENYLALNINE N METHYLAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE; MARIMASTAT; METALLOPROTEINASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; CELL SURFACE; CONTROLLED STUDY; CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE ACTIVATED CELL SORTER; GENE EXPRESSION; HUMAN CELL; MONOCYTE; NONHUMAN; PRIORITY JOURNAL;

CELL LINE; CELL MEMBRANE; CYTOKINES; HUMANS; LIPOPOLYSACCHARIDES; METALLOENDOPEPTIDASES; MONOCYTES; TETRADECANOYLPHORBOL ACETATE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032961006     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(98)00300-1     Document Type: Article

References (38)

1. Jue D.-M., Sherry B., Luedke C., Manogue K.R., Cerami A. Processing of newly synthesized cachectin/tumor necrosis factor in endotoxin-stimulated macrophages. Biochemistry. 29:1990;8371-8377.
2. Black R.A., Durie F.H., Otten-Evans C., Miller R., Slack J.L., Lynch D.H., Castner B., Mohler K.M., Gerhart M., Johnson R.S., Itoh Y., Okada Y., Nagase H. Relaxed specificity of matrix metalloproteinases (MMPS) and TIMP insensitivity of tumor necrosis factor-α (TNF-α) production suggest the major TNF-α converting enzyme is not an MMP. Biochem Biophys Res Commun. 225:1996;400-405.
3. Gearing A.J.H., Beckett P., Christodoulou M., Churchill M., Clements J., Drummond A.H., Galloway W.A., Gilbert R., Gordon J.L., Leber T.M., Mangan M., Miller K., Nayee P., Owen K., Patel S., Thomas W., Wells G., Wood L.M., Woolley K. Processing of tumour necrosis factor-α by metalloproteinases. Nature. 370:1994;555-557.
4. Gearing A.J.H., Beckett P., Christodoulou M., Churchill M., Clements J.M., Crimmin M., Davidson A.H., Drummond A.H., Galloway W.A., Gilbert R., Gordon J.L., Leber T.M., Mangan M., Miller K., Nayee P., Owen K., Patel S., Thomas W., Wells G., Wood L.M., Woolley K. Matrix metalloproteinases and processing of pro-TNF-α J Leukoc Biol. 57:1995;774-777.
5. McGeehan G.M., Becherer J.D., Bast R. Jr, Boyer C.M., Champion B., Connolly K.M., Conway J.G., Furdon P., Karp S., Kidao S., McElroy A.B., Nichols J., Pryzwansky K.M., Schoenen F., Sekut L., Truesdale A., Verghese M., Warner J., Ways J.P. Regulation of tumour necrosis factor-α processing by a metalloproteinase inhibitor. Nature. 370:1994;558-561.
6. Mohler K.M., Sleath P.R., Fitzner J.N., Cerretti D.P., Alderson M., Kerwar S., Torrance D.S., Otten-Evans C., Greenstreet T., Weerawarna K., Kronheim S.R., Petersen M., Gerhart M., Kozlosky C.J., March C.J., Black R.A. Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing. Nature. 370:1994;218-220.
7. Black R.A., Rauch C.T., Kozlosky C.J., Peschon J.J., Slack J.L., Wolfson M.F., Castner B.J., Stocking K.L., Reddy P., Srinivasan S., Nelson N., Boiani N., Schooley K.A., Gerhart M., Davis R., Fitzner J.N., Johnson R.S., Paxton R.J., March C.J., Cerretti D.P. A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells. Nature. 385:1997;729-733.
8. Moss M.L., Jin S.-L.C., Milla M.E., Burkhart W., Carter H.L., Chen W., Clay W.C., Didsbury J.R., Hassler D., Hoffman C.R., Kost T.A., Lambert M.H., Leesnitzer M.A., McCauley P., McGeehan G., Mitchell J., Moyer M., Pahel G., Rocque W., Overton L.K., Schoenen F., Seaton T., Su J.-L., Warner J., Willard D., Becherer J.D. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-α Nature. 385:1997;733-736.
9. Wolfsberg T.G., Primakoff P., Myles D.G., White J.M. ADAM, a novel family of membrane proteins containing A Disintegrin And Metalloprotease Domain Multipotential functions in cell-cell and cell-matrix interactions . J Cell Biol. 131:1995;275-278.
10. Robache-Gallea S., Bruneau J.-M., Robbe H., Morand V., Capdevila C., Bhatnagar N., Chouaib S., Roman-Roman S. Partial purification and characterization of a tumor necrosis factor-α converting activity. Eur J Immunol. 27:1997;1275-1282.
11. Solorzano C.C., Ksontini R., Pruitt J.H., Auffenberg T., Tannahill C., Galardy R.E., Schultz G.P., MacKay S.L.D., Copeland E.M. III, Moldawer L.L. A matrix metalloproteinase inhibitor prevents processing of tumor necrosis factor α (TNFα) and abrogates endotoxin-induced lethality. Shock. 7:1997;427-431.
12. Decoster E., Vanhaesebroeck B., Vandenabeele P., Grooten J., Fiers W. Generation and biological characterization of membrane-bound uncleavable murine tumor necrosis factor. J Biol Chem. 270:1995;18473-18478.
13. Perez C., Albert I., DeFay K., Zachariades N., Gooding L., Kriegler M. A nonsecretable cell surface mutant of tumor necrosis factor (TNF) kills by cell-to-cell contact. Cell. 63:1990;251-258.
14. Williams L.M., Gibbons D.L., Gearing A., Maini R.N., Feldmann M., Brennan F.M. Paradoxical effects of a synthetic metalloproteinase inhibitor that blocks both p55 and p75 TNF receptor shedding and TNFα processing in RA synovial membrane cell cultures. J Clin Invest. 97:1996;2833-2841.
15. Elliott M.J., Maini R.N., Feldmann M., Long-Fox A., Charles P., Katsikis P., Brennan F.M., Walker J., Bijl H., Ghrayeb J., Woody J.N. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α Arthritis Rheum. 36:1993;1681-1690.
16. Elliott M.J., Maini R.N., Feldmann M., Kalden J.R., Antoni C., Smolen J.S., Leeb B., Breedveld F.C., Macfarlane J.D., Bijl H., Woody J.N. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet. 344:1994;1105-1110.
17. Elliott M.J., Maini R.N., Feldmann M., Long-Fox A., Charles P., Bijl H., Woody J.N. Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritis. Lancet. 344:1994;1125-1127.
18. Elliott M.J., Maini R.N. Anti-cytokine therapy in rheumatoid arthritis. Baillieres Clin Rheumatol. 9:1995;633-652.
19. Rankin E.C.C., Choy E.H.S., Kassimos D., Kingsley G.H., Sopwith A.M., Isenberg D.A., Panayi G.S. The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis. Br J Rheumatol. 34:1995;334-342.
20. Targan S.R., Hanauer S.B., van Deventer S.J.H., Mayer L., Present D.H., Braakman T., DeWoody K.L., Schaible T.F., Rutgeerts P.J. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease. N Engl J Med. 337:1997;1029-1035.
21. Beckett R.P., Davidson A.H., Drummond A.H., Huxley P., Whittaker M. Recent advances in matrix metalloproteinase inhibitor research. Drug Dis Today. 1:1996;16-26.
22. Vey E., Burger D., Dayer J.-M. Expression and cleavage of tumor necrosis factor-α and tumor necrosis factor receptors by human monocytic cell lines upon direct contact with stimulated T cells. Eur J Immunol. 26:1996;2404-2409.
23. Chaudhri G. Differential regulation of biosynthesis of cell surface and secreted TNF-α in LPS-stimulated murine macrophages. J Leukoc Biol. 62:1997;249-257.
24. Lunn C.A., Fan X., Dalie B., Miller K., Zavodny P.J., Narula S.K., Lundell D. Purification of ADAM 10 from bovine spleen as a TNFα convertase. FEBS Lett. 400:1997;333-335.
25. Rosendahl M.S., Ko S.C., Long D.L., Brewer M.T., Rosenzweig B., Hedil E., Anderson L., Pyle S.M., Moreland J., Meyers M.A., Kohno T., Lyons D., Lichenstein H.S. Identification and characterization of a pro-tumor necrosis factor-α-processing enzyme from the ADAM family of zinc metalloproteases. J Biol Chem. 272:1997;24588-24593.
26. Solomon K.A., Covington M.B., DeCicco C.P., Newton R.C. The fate of pro-TNFα following inhibition of metalloprotease-dependent processing to soluble TNFα in human monocytes. J Immunol. 159:1997;4524-4531.
27. Georgopoulos S., Plows D., Kollias G. Transmembrane TNF is sufficient to induce localized tissue toxicity and chronic inflammatory arthritis in transgenic mice. J Inflamm. 46:1996;86-97.
28. Neurath M.F., Fuss I., Pasparakis M., Alexopoulou L., Haralambous S., Meyerzum Buschenfelde K.H., Strober W., Kollias G. Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice. Eur J Immunol. 27:1997;1743-1750.
29. Tomasovic S.P., Khodadadian M., Hung M.C., Klostergaard J. Hyperthermia enhances the cytotoxicity of National Institutes of Health 3T3 cells transfected with a noncleavable transmembrane pro-tumor necrosis factor deletion mutant. J Immunother. 16:1994;181-187.
30. Probert L., Akassaglou K., Alexopoulou L., Douni E., Haralambous S., Hill S., Kassiotis G., Kontoyiannis D., Pasparakis M., Plows D., Kollias G. Dissection of the pathologies induced by transmembrane and wild-type tumor necrosis factor in transgenic mice. J Leukoc Biol. 59:1996;518-525.
31. Solorzano C.C., Ksontini R., Pruitt H.H., Hess P.J., Edwards P.D., Kaibara A., Abouhamze A., Auffenberg T., Galardy R.E., Vauthey J.N., Copeland E.M. III, Edwards C.K. III, Lauwers G.Y., Clare-Salzler M., MacKay S.L.D., Moldawer L.L., Lazarus D.D. Involvement of 26-kDa cell-associated TNF-α in experimental hepatitis and exacerbation of liver injury with a matrix metalloproteinase inhibitor. J Immunol. 158:1997;414-419.
32. Gattorno M., Picco P., Buoncompagni A., Stalla F., Facchetti P., Sormani M.P., Pistoia V. Serum p55 and p75 tumour necrosis factor receptors as markers of disease activity in juvenile chronic arthritis. Ann Rheum Dis. 55:1996;243-247.
33. Gattorno M., Picco P., Buoncompagni A., Stalla F., Pistoia V. Tumor necrosis factor receptor p75 correlates better than p55 with disease activity in juvenile rheumatoid arthritis Comment to the article by Mangge et al . Arthritis Rheum. 39:1996;883-884.
34. Bjornberg F., Lantz M., Gullberg U. Metalloproteases and serineproteases are involved in the cleavage of the two tumor necrosis factor (TNF) receptors to soluble forms in the myeloid cell lines U-937 and THP-1. Scand J Immunol. 42:1995;418-424.
35. Hwang C., Gatanaga M., Granger G.A., Gatanaga T. Mechanism of release of soluble forms of tumor necrosis factor/lymphotoxin receptors by phorbol myristate acetate-stimulated human THP-1 cells in vitro. J Immunol. 151:1993;5631-5638.
36. Gallea-Robache S., Morand V., Millet S., Bruneau J.M., Bhatnagar N., Chouaib S., Roman-Roman S. A metalloproteinase inhibitor blocks the shedding of soluble cytokine receptors and processing of transmembrane cytokine precursors in human monocytic cells. Cytokine. 9:1997;340-346.
37. Crowe P.D., Walter B.N., Mohler K.M., Otten-Evans C., Black R.A., Ware C.F. A metalloprotease inhibitor blocks shedding of the 80-kDa TNF receptor and TNF processing in T lymphocytes. J Exp Med. 181:1995;1205-1210.
38. Alexopoulou L., Pasparakis M., Kollias G. A murine transmembrane tumor necrosis factor (TNF) transgene induces arthritis by cooperative p55/p75 TNF receptor signaling. Eur J Immunol. 27:1997;2588-2592.